Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

NCT00147121 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, B-Cell

Interventions

DRUG: Rituximab + Standard CHOP
DRUG: Rituximab + Bi-weekly CHOP

Sponsor

Haruhiko Fukuda

Collaborators

[object Object]